Epcoritamab, a novel, subcutaneous cd3xcd20 bispecific t-cell-engaging antibody, in relapsed or refractory large b-cell lymphoma: dose expansion in a phase i/ii trial

HIGHLIGHTS

• who: Catherine Thieblemont and colleagues from the Assistance Publique and Hou0302pitaux de Paris (APHP), Hou0302pital Saint-Louis, Hu00e9mato-oncologie, Universitu00e9 de Paris, Paris, France , University of Michigan Comprehensive Cancer Center, Ann Arbor, MI , Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bu00e9nite, France , Sir Charles Gairdner Hospital, Perth, Australia , Division of Internal Medicine, Medical School, University of Western Australia, Perth, Australia , Vejle Hospital, Vejle, Denmark , The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom , Keimyung University Dongsan Medical Center, Daegu, Republic of Korea , Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ , Concord Hospital, University of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.